A recently discovered cellular protein can be used to treat prostate cancer. The protein ubiquitin when attached to the EGFR, can cause degeneration of cell.
![New Cellular Protein can be used to Treat Prostate Cancer New Cellular Protein can be used to Treat Prostate Cancer](https://images.medindia.net/health-images/1200_1000/prostate-cancer-treatment1.jpg)
‘When the researchers used signal-transducing adaptor protein-2 (STAP-2), the prostate cancer cells did not form into a tumor, which could potentially make the STAP-2 inhibitors play a role in treating Gefitinib-resistant prostate cancers.’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
EGFR, present on the cell membrane, is involved in cell proliferation and the development of dermis, lung, and digestive tissues. When a mutation causes its over-activation, it can lead to increased cell proliferation and tumor formation.![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Tadashi Matsuda of Hokkaido University and his colleagues in Japan investigated human prostate cancer cells to determine if there is an unknown up-regulation mechanism in the EGFR pathway.
When EGFR is attached to a small protein called ubiquitin, it is given "the kiss of death" and tagged for degradation inside the cell. This tagging process is facilitated by a protein called c-CBL.
The degradation of EGFR leads to less signaling from the receptor and reduced cell proliferation.
Matsuda and his team found that signal-transducing adaptor protein-2 (STAP-2) stabilizes EGFR by inhibiting its c-CBL-mediated ubiquitination.
Advertisement
"STAP-2 inhibitors could play a role in treating Gefitinib-resistant prostate cancers. Further studies on STAP-2 will provide new insights into cancer physiology and support the development of anticancer therapies," says Tadashi Matsuda.
Advertisement
Source-Eurekalert